vs
FIRST BUSEY CORP（BUSE）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是FIRST BUSEY CORP的1.1倍（$207.3M vs $196.2M），FIRST BUSEY CORP净利率更高（25.5% vs -62.0%，领先87.5%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 29.9%）
第一布西银行是总部位于美国伊利诺伊州尚佩恩的金融机构，业务覆盖伊利诺伊州、印第安纳州以及佛罗里达州西南部，隶属于金融控股公司First Busey Holding。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
BUSE vs RARE — 直观对比
营收规模更大
RARE
是对方的1.1倍
$196.2M
净利率更高
BUSE
高出87.5%
-62.0%
两年增速更快
RARE
近两年复合增速
29.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $196.2M | $207.3M |
| 净利润 | $50.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 25.5% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | 266.7% | 3.5% |
| 每股收益（稀释后） | $1.00 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BUSERARE
| Q1 26 | $196.2M | — | ||
| Q4 25 | $200.2M | $207.3M | ||
| Q3 25 | $196.3M | $159.9M | ||
| Q2 25 | $198.0M | $166.5M | ||
| Q1 25 | $125.0M | $139.3M | ||
| Q4 24 | $116.8M | $164.6M | ||
| Q3 24 | $118.5M | $139.5M | ||
| Q2 24 | $116.2M | $147.0M |
净利润BUSERARE
| Q1 26 | $50.0M | — | ||
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $57.1M | $-180.4M | ||
| Q2 25 | $47.4M | $-115.0M | ||
| Q1 25 | $-30.0M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $32.0M | $-133.5M | ||
| Q2 24 | $27.4M | $-131.6M |
营业利润率BUSERARE
| Q1 26 | — | — | ||
| Q4 25 | 38.7% | -54.7% | ||
| Q3 25 | 39.4% | -106.9% | ||
| Q2 25 | 32.6% | -64.8% | ||
| Q1 25 | -26.1% | -102.6% | ||
| Q4 24 | 32.0% | -74.3% | ||
| Q3 24 | 35.9% | -94.6% | ||
| Q2 24 | 33.1% | -79.1% |
净利率BUSERARE
| Q1 26 | 25.5% | — | ||
| Q4 25 | — | -62.0% | ||
| Q3 25 | 29.1% | -112.8% | ||
| Q2 25 | 23.9% | -69.0% | ||
| Q1 25 | -24.0% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 27.0% | -95.7% | ||
| Q2 24 | 23.5% | -89.5% |
每股收益（稀释后）BUSERARE
| Q1 26 | $1.00 | — | ||
| Q4 25 | $0.81 | $-1.28 | ||
| Q3 25 | $0.58 | $-1.81 | ||
| Q2 25 | $0.52 | $-1.17 | ||
| Q1 25 | $-0.44 | $-1.57 | ||
| Q4 24 | $0.50 | $-1.34 | ||
| Q3 24 | $0.55 | $-1.40 | ||
| Q2 24 | $0.47 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $288.5M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.5B | $-80.0M |
| 总资产 | $18.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BUSERARE
| Q1 26 | $288.5M | — | ||
| Q4 25 | $294.1M | $421.0M | ||
| Q3 25 | $385.5M | $202.5M | ||
| Q2 25 | $752.4M | $176.3M | ||
| Q1 25 | $1.2B | $127.1M | ||
| Q4 24 | $697.7M | $174.0M | ||
| Q3 24 | $553.7M | $150.6M | ||
| Q2 24 | $285.3M | $480.7M |
总债务BUSERARE
| Q1 26 | — | — | ||
| Q4 25 | $113.8M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益BUSERARE
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.5B | $-80.0M | ||
| Q3 25 | $2.4B | $9.2M | ||
| Q2 25 | $2.4B | $151.3M | ||
| Q1 25 | $2.2B | $144.2M | ||
| Q4 24 | $1.4B | $255.0M | ||
| Q3 24 | $1.4B | $346.8M | ||
| Q2 24 | $1.3B | $432.4M |
总资产BUSERARE
| Q1 26 | $18.1B | — | ||
| Q4 25 | $18.1B | $1.5B | ||
| Q3 25 | $18.2B | $1.2B | ||
| Q2 25 | $18.9B | $1.3B | ||
| Q1 25 | $19.5B | $1.3B | ||
| Q4 24 | $12.0B | $1.5B | ||
| Q3 24 | $12.0B | $1.5B | ||
| Q2 24 | $12.0B | $1.6B |
负债/权益比BUSERARE
| Q1 26 | — | — | ||
| Q4 25 | 0.05× | — | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流BUSERARE
| Q1 26 | — | — | ||
| Q4 25 | $192.6M | $-99.8M | ||
| Q3 25 | $62.5M | $-91.4M | ||
| Q2 25 | $49.5M | $-108.3M | ||
| Q1 25 | $8.4M | $-166.5M | ||
| Q4 24 | $178.3M | $-79.3M | ||
| Q3 24 | $60.1M | $-67.0M | ||
| Q2 24 | $28.5M | $-77.0M |
自由现金流BUSERARE
| Q1 26 | — | — | ||
| Q4 25 | $173.0M | $-100.8M | ||
| Q3 25 | $54.5M | $-92.7M | ||
| Q2 25 | $46.1M | $-110.7M | ||
| Q1 25 | $6.6M | $-167.8M | ||
| Q4 24 | $171.8M | $-79.5M | ||
| Q3 24 | $59.1M | $-68.6M | ||
| Q2 24 | $26.3M | $-79.0M |
自由现金流率BUSERARE
| Q1 26 | — | — | ||
| Q4 25 | 86.4% | -48.6% | ||
| Q3 25 | 27.7% | -58.0% | ||
| Q2 25 | 23.3% | -66.5% | ||
| Q1 25 | 5.3% | -120.5% | ||
| Q4 24 | 147.1% | -48.3% | ||
| Q3 24 | 49.9% | -49.2% | ||
| Q2 24 | 22.6% | -53.7% |
资本支出强度BUSERARE
| Q1 26 | — | — | ||
| Q4 25 | 9.8% | 0.5% | ||
| Q3 25 | 4.1% | 0.8% | ||
| Q2 25 | 1.7% | 1.5% | ||
| Q1 25 | 1.4% | 1.0% | ||
| Q4 24 | 5.5% | 0.1% | ||
| Q3 24 | 0.8% | 1.2% | ||
| Q2 24 | 1.9% | 1.4% |
现金转化率BUSERARE
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.09× | — | ||
| Q2 25 | 1.04× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.88× | — | ||
| Q2 24 | 1.04× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BUSE
| Net Interest Income | $154.0M | 78% |
| Noninterest Income | $42.3M | 22% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
